Regulus Therapeutics Inc. (NASDAQ:RGLS) shares saw an uptick in trading volume on Tuesday . 376,307 shares changed hands during mid-day trading, an increase of 6% from the previous session’s volume of 355,610 shares.The stock last traded at $3.46 and had previously closed at $3.28.

A number of research firms recently issued reports on RGLS. BMO Capital Markets downgraded Regulus Therapeutics from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $16.00 to $4.00 in a research report on Tuesday, June 28th. FBR & Co reaffirmed an “outperform” rating and issued a $9.00 target price (down previously from $30.00) on shares of Regulus Therapeutics in a research report on Tuesday, June 28th. Chardan Capital lowered their target price on Regulus Therapeutics from $14.50 to $12.00 and set a “buy” rating on the stock in a research report on Monday, July 25th. Wedbush reaffirmed an “outperform” rating and issued a $15.00 target price on shares of Regulus Therapeutics in a research report on Wednesday, August 3rd. Finally, Needham & Company LLC lowered their target price on Regulus Therapeutics from $25.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, June 28th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Regulus Therapeutics has a consensus rating of “Buy” and a consensus price target of $10.17.

The firm has a 50-day moving average price of $3.42 and a 200 day moving average price of $5.06. The firm’s market cap is $181.70 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/regulus-therapeutics-inc-rgls-sees-unusually-high-trading-volume.html

Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.38) by $0.02. Regulus Therapeutics had a negative return on equity of 56.13% and a negative net margin of 456.47%. On average, analysts forecast that Regulus Therapeutics Inc. will post ($1.59) EPS for the current year.

Several institutional investors have recently added to or reduced their stakes in RGLS. Rhumbline Advisers boosted its position in Regulus Therapeutics by 32.2% in the second quarter. Rhumbline Advisers now owns 35,762 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 8,720 shares during the period. ProShare Advisors LLC boosted its position in Regulus Therapeutics by 3.7% in the second quarter. ProShare Advisors LLC now owns 44,037 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 1,561 shares during the period. Wedbush Securities Inc. boosted its position in Regulus Therapeutics by 43.4% in the second quarter. Wedbush Securities Inc. now owns 47,061 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 14,246 shares during the period. Alliancebernstein L.P. boosted its position in Regulus Therapeutics by 112.2% in the second quarter. Alliancebernstein L.P. now owns 47,100 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 24,900 shares during the period. Finally, Swiss National Bank boosted its position in Regulus Therapeutics by 9.2% in the second quarter. Swiss National Bank now owns 58,200 shares of the biopharmaceutical company’s stock worth $168,000 after buying an additional 4,900 shares during the period. 51.47% of the stock is currently owned by institutional investors.

About Regulus Therapeutics

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

5 Day Chart for NASDAQ:RGLS

Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.